Navigation Links
Pivotal Phase 3 Data from Boehringer Ingelheim Hepatitis C Portfolio to be Presented at 64th Annual AASLD Meeting
Date:10/1/2013

tolerability of faldaprevir in patients

with different levels of renal impairment

F. Huang

ID# 466
Session: HCV Therapy: The
Developmental Pipeline
Date: Sat, Nov. 2
Time: 2:00 PM – 7:30 PM ET
Location: Poster Hall Effect of steady-state faldaprevir

on the pharmacokinetics of steady-state

methadone and buprenorphine/naloxone

in subjects on stable addiction

management therapy

D. Joseph

ID# 483
Session: HCV Therapy: The
Developmental Pipeline
Date: Sat, Nov. 2
Time: 2:00 PM – 7:30 PM ET
Location: Poster Hall A pooled analysis of two randomized,

double-blind placebo-controlled

Phase III trials (STARTVerso1&2) of

faldaprevir plus pegylated interferon

alfa-2a and ribavirin in treatment-naive

patients with chronic hepatitis C

genotype-1 infection

D. Jensen

ID# 1088
Session: HCV Therapeutics: New
Agents
Date: Sun, Nov. 3
Time: 8:00 AM – 5:30 PM ET
Location: Poster Hall Subgroup analyses and baseline

predictors of response with faldaprevir

plus pegylated interferon alfa-2a

and ribavirin in treatment-naive patients

with chronic hepatitis C genotype-1

infection: a pooled analysis of

STARTVerso1 and 2

E.M. Yoshida

ID# 1114
Session: HCV Therapeutics: New
Agents
Date: Sun, Nov. 3
Time: 8:00 AM – 5:30 PM ET
Location: Poster Hall STARTVerso3: A randomized,

double-blind, placebo-controlled

Phase III trial of faldaprevir in

combination with pegylated interferon

alfa-2a and ribavirin in

treatment-experienced patients with

chronic hepatitis C genotype-1 infection

I. Jacobson

ID# 1100
Session: HCV Therapeutics: New
Agents
Date: Sun, Nov. 3
Time: 8:00 AM – 5:30 PM ET
Location: Po
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials
2. Shield Therapeutics Completes Recruitment to Pivotal Phase 3 Programme for Treatment of Iron Deficiency
3. CSL Behring Doses First Patient in Part 3 of Global Phase I/III Pivotal Study of rVIII-SingleChain (Recombinant Single-Chain Factor VIII) for Treatment of Hemophilia A
4. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
5. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
6. Relievant Medsystems Achieves Completion of Interim Safety Data Analysis of Intracept in SMART Pivotal Study and Expands Senior Leadership Team
7. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
8. Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
9. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
10. First U.S. Patients Treated in PneumRx RENEW Pivotal Study for Treatment of Severe Emphysema
11. ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014  CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced an ... lead drug candidate, aldoxorubicin.  The presentation, titled, "Drug ... will be given by Sant P. Chawla ... Center and principal investigator of the Company,s ongoing ...
(Date:10/30/2014)... -- , La fórmula de leche ... tolerancia a la proteína de leche de vaca  ... leche de la vaca (APLV) es la principal alergia alimentaria ... APLV se trataba eliminando las proteínas lácteas de ... posible adquirir tolerancia oral en un número significativo ...
(Date:10/30/2014)... Oct. 30, 2014  TWi Pharmaceuticals, Inc. today announced ... States Food and Drug Administration (FDA) on its Abbreviated ... 23 mg, the generic equivalent to Eisai Inc.,s Aricept® ... patients. TWi Pharmaceuticals is preparing to launch ... subsidiary, TWi Pharmaceuticals USA , at ...
Breaking Medicine Technology:CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3
... 28, 2011 Nile Therapeutics, Inc. (Nasdaq: ... novel therapeutics for heart failure patients, today announced plans ... ) on the clinical development of Nile,s proprietary natriuretic ... disease applications. "We are very pleased to ...
... Feb. 28, 2011 PAREXEL International Corporation (Nasdaq: ... presenting at the Raymond James Investors Conference in Orlando, FL. ... be making a presentation on PAREXEL at 2:50 p.m.  ET ... of this presentation will be available through the "Investors" ...
Cached Medicine Technology:Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 2Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 3PAREXEL International to Present at Raymond James Investors Conference 2
(Date:10/28/2014)... that aims to make personalized medicine a reality for ... across British Columbia. , The "Genomics for Precision Drug ... of its kind in North America. The project is ... (BCPhA), with the research component led by a team ... Sciences (UBC). It will position the pharmacist as the ...
(Date:10/27/2014)... price tag for informal caregiving of elderly people by ... $522 billion a year, according to a new RAND ... care at minimum wage would cost $221 billion, while ... $642 billion annually. , The study, published online ... estimates about the value of informal caregiving by making ...
(Date:10/27/2014)... different role than previously thought in the opening and ... out of our cells, researchers at Johns Hopkins report. ... right concentrations of sodium and calcium ions in cells ... processes. The new study reveals that a form of ... channels wide. The finding is likely to bring new ...
(Date:10/27/2014)... The 2014 Sharp­Brains Vir­tual ... world’s top sci­en­tists and inno­va­tors work­ing on ... via neuroscience-based inno­va­tion. , Indi­vid­u­als and insti­tu­tions ... bil­lion in 2014 in web-based, mobile and ... func­tion. Growth is poised to con­tinue, fueled ...
(Date:10/27/2014)... Agency (EMA), an EU agency, has gathered information on ... European ADR database, EudraVigilance. Both authorities and pharmaceutical companies ... the database, which provides new knowledge about unknown and ... drug reaction reports on asthma medications approved for – ... (2007 to 2011). In the light of the total ...
Breaking Medicine News(10 mins):Health News:Genomics helps pharmacists target the right drugs for the right patient 2Health News:Cost of informal caregiving for US elderly is $522 billion annually, study finds 2Health News:200 Experts to Discuss and Shape the Future of Brain Health, Gathered Around a Virtual Table 2Health News:200 Experts to Discuss and Shape the Future of Brain Health, Gathered Around a Virtual Table 3Health News:200 Experts to Discuss and Shape the Future of Brain Health, Gathered Around a Virtual Table 4Health News:Adverse drug reactions in children following use of asthma medications 2
... a pregnancy take a general multivitamin supplement in the ... them and their baby, however a recent survey suggests ... in unborn babies but many women do not consider ... based on a recent survey. The survey conducted by ...
... has donated $50,000 to Gilda's Club Worldwide, //an organization that ... in a statement: "When children have cancer, or when their ... places they can turn to for support." , ,"Gilda's ... helping children in need, and so I am very happy ...
... People suffering from Alzheimer’s disease can have loss of ... to test their visual clarity., ,Alzheimer’s disease affects ... symptoms of the disease are decreasing memory, ability to ... Alzheimer’s disease are often disoriented too much to be ...
... may lack a gene called estrogen receptor beta and not ... research funded by National Institute of Environmental Health Sciences reported ... role in moving the egg outside the ovary to be ... is found otherwise throughout in the female reproductive tissues, women ...
... people were infected with HIV by 2004.// This puts the prevalence ... South Africa 's total population is 46.9 million. , ... far higher than the estimate of 4.5 million given by the ... ,The health department said that between 6.29 million ...
... microRNAs may be responsible for birth defects, cancer and ... Institute have used genetically modified mice to see how ... animals. When the mice were grown without the microRNA ... limbs., ,MicroRNA (miRNA) are small RNA molecules that ...
Cached Medicine News:Health News:Britney Spears Donates $50 000 To Support Cancer Patients 2Health News:Britney Spears Donates $50 000 To Support Cancer Patients 3Health News:Over Six Million HIV Infected People In South Africa- Finds A Survey 2Health News:Over Six Million HIV Infected People In South Africa- Finds A Survey 3
0.6mm Tip x10mm Shaft, Straight Shaft, 90 Degree Hook at Tip; overall length 120mm; in Titianium....
... SURPASS Perfusion Catheter is indicated ... stenotic portion of a coronary ... for the purpose of improving ... Catheters are also designed to ...
16mm from Mid-screw to Tips, blunt tips; overall length 110mm; Stainless Steel...
16mm from Mid-Screw to Blunt Tips, Gently Curved Blades; overall length 120mm; Stainless Steel...
Medicine Products: